Protalix BioTherapeutics (PLX) Earnings Date, Estimates & Call Transcripts → Crypto Pioneer Says: “The last crypto bull market has begun.” (From InvestorPlace) (Ad) Free PLX Stock Alerts $1.14 -0.03 (-2.56%) (As of 05/17/2024 08:54 PM ET) Add Compare Share Share EarningsStock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsSocial MediaStock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsSocial Media Earnings SummaryLatest Earnings DateMay. 10EstimatedActual EPS (May. 10) -$0.06 Missed By -$0.06 Read Call TranscriptListen to Call Skip Charts & View Estimated and Actual Earnings DataEarnings Per ShareRevenuePLX Earnings Estimates and Actuals by QuarterEarnings Estimates and Acutals by Quarter Chart DescriptionThe chart below shows up to four years of a company's earnings history. The dark blue line represents the company's actual earnings per share. The light blue area represents the range of Wall Street analysts' earnings estimates for each quarter.PLX Estimated and Actual Revenue by Quarter Estimated Revenue and Actual Revenue by Quarter Chart DescriptionThe chart below shows up to four years of a company's revenue history. The dark blue line represents the company's actual revenue. The light blue line represents the company's estimated revenue based on the consensus of Wall Street analysts for each quarter. Ad Manward PressShocking: One AI startup's revenue could surge 4,735%Shocking: One AI Startup's Revenue Could Surge 4,735% While Nvidia gets all the attention, one small AI startup is quietly positioning itself to be the biggest winner.Click here to discover the AI chip company Protalix BioTherapeutics Analyst EPS EstimatesQuarterNumber of EstimatesLow EstimateHigh EstimateAverage EstimateQ4 20241$0.10$0.10$0.10PLX Earnings Date and InformationProtalix BioTherapeutics last posted its quarterly earnings results on May 10th, 2024. The reported ($0.06) earnings per share for the quarter. The firm earned $3.75 million during the quarter. Protalix BioTherapeutics has generated $0.04 earnings per share over the last year ($0.04 diluted earnings per share) and currently has a price-to-earnings ratio of 28.5. Earnings for Protalix BioTherapeutics are expected to grow by 425.00% in the coming year, from $0.12 to $0.63 per share. Read More Protalix BioTherapeutics Earnings History by Quarter Custom Range 3 Months 6 Months Year-to-Date 1 Year 2 Years 3 Years 5 Years Time Frame * Start Date * End Date Export to Excel DateQuarterConsensus EstimateReported EPSBeat/MissGAAP EPSRevenue EstimateActual RevenueCall Transcript5/10/2024Q1 2024-($0.06)($0.06)($0.06)-$3.75 million 3/14/2024Q4 2023($0.03)($0.07)($0.04)($0.07)$8.15 million$10.49 million 11/6/2023Q3 2023($0.07)($0.04)+$0.03($0.04)$7.64 million$10.35 million 8/7/2023Q2 2023($0.04)$0.21+$0.25$0.21$10.22 million$35.08 million8/7/2023Q2 2023($0.04)$0.21+$0.25$0.21$10.22 million$35.08 million 5/4/2023Q1 2023-($0.05)($0.05)($0.05)-$9.59 millionCrypto Pioneer Says: “The last crypto bull market has begun.” (Ad)Right now, there’s over $6 trillion in potential investment money waiting on the sidelines. That means this crypto bull market has a lot more room to run before it comes close to being a bubble.Click here if you’d like to learn more about these five cryptos…5/4/2023Q1 2023-($0.05)($0.05)($0.05)-$9.59 million2/27/2023Q4 2022($0.15)($0.07)+$0.08($0.07)$6.12 million$8.62 million2/27/2023Q4 2022($0.15)($0.07)+$0.08($0.07)$6.12 million$8.62 million2/27/2023Q4 2022($0.15)($0.07)+$0.08($0.07)$6.12 million$8.62 million11/14/2022Q3 2022($0.15)($0.07)+$0.08($0.07)$5.69 million$14.18 million11/14/2022Q3 2022($0.15)($0.07)+$0.08($0.07)$5.69 million$14.18 million11/14/2022Q3 2022($0.15)($0.07)+$0.08($0.07)$5.69 million$14.18 million8/15/2022Q2 2022($0.18)($0.11)+$0.07($0.11)$2.68 million$8.75 million8/15/2022Q2 2022($0.18)($0.11)+$0.07($0.11)$2.68 million$8.75 million8/15/2022Q2 2022($0.18)($0.11)+$0.07($0.11)$2.68 million$8.75 million 5/16/2022Q1 2022-($0.05)($0.05)($0.05)-$16.09 million5/16/2022Q1 2022-($0.05)($0.05)($0.05)-$16.09 million5/16/2022Q1 2022-($0.05)($0.05)($0.05)-$16.09 million3/31/2022Q4 2021($0.11)($0.14)($0.03)($0.14)$7.79 million$8.55 million3/31/2022Q4 2021($0.11)($0.14)($0.03)($0.14)$7.79 million$8.55 million3/31/2022Q4 2021($0.11)($0.14)($0.03)($0.14)$7.79 million$8.55 million11/15/2021Q3 2021($0.12)($0.09)+$0.03($0.09)$6.90 million$12.05 million11/15/2021Q3 2021($0.12)($0.09)+$0.03($0.09)$6.90 million$12.05 million11/15/2021Q3 2021($0.12)($0.09)+$0.03($0.09)$6.90 million$12.05 million 8/16/2021Q2 2021($0.08)($0.25)($0.17)($0.25)$8.30 million$6.43 million8/16/2021Q2 2021($0.08)($0.25)($0.17)($0.25)$8.30 million$6.43 million8/15/2021Q2($0.08)($0.25)($0.17)($0.25)$8.30 million$6.43 million Protalix BioTherapeutics Earnings - Frequently Asked Questions When did Protalix BioTherapeutics announce their last quarterly earnings? Protalix BioTherapeutics (NYSE:PLX) last announced its quarterly earning data on Friday, May 10, 2024. Learn more on PLX's earnings history. How can I listen to Protalix BioTherapeutics's earnings conference call? The conference call for Protalix BioTherapeutics's latest earnings report can be listened to online. Listen to Conference Call How can I read Protalix BioTherapeutics's conference call transcript? The conference call transcript for Protalix BioTherapeutics's latest earnings report can be read online. Read Transcript How much revenue does Protalix BioTherapeutics generate each year? Protalix BioTherapeutics (NYSE:PLX) has a recorded annual revenue of $65.49 million. How much profit does Protalix BioTherapeutics generate each year? Protalix BioTherapeutics (NYSE:PLX) has a recorded net income of $8.31 million. PLX has generated $0.04 earnings per share over the last four quarters. What is Protalix BioTherapeutics's price-to-earnings ratio? Protalix BioTherapeutics (NYSE:PLX) has a trailing price-to-earnings ratio of 28.50 and a forward price-to-earnings ratio of 9.50. What is Protalix BioTherapeutics's EPS forecast for next year? Protalix BioTherapeutics's earnings are expected to grow from $0.12 per share to $0.63 per share in the next year, which is a 425.00% increase. More Earnings Resources from MarketBeat Related Companies: DTIL Earnings Results GRTS Earnings Results ATHA Earnings Results ELUT Earnings Results ALVR Earnings Results PASG Earnings Results TIL Earnings Results CGTX Earnings Results CVM Earnings Results ATRA Earnings Results Earnings Tools: Today's Earnings Tomorrow's Earnings Next Week's Earnings Upcoming Earnings Calls Earnings Newsletter Earnings Call Transcripts Earnings Beats & Misses Corporate Guidance Earnings Screener Earnings By Country: U.S. Earnings Reports Canadian Earnings Reports U.K. Earnings Reports Australia Earnings Reports Latest Articles: Baidu Stock Earnings Prove Ray Dalio Right about China?Home Depot: Earnings Mixed, Wait to Buy the DipTraders Sell but Investors Still Win After Palantir's EarningsTech Earnings Insights: Where Opportunity Meets UncertaintyApple’s Earnings Show Investors Its Strength and Its WeaknessCarvana’s Q1 Earnings: A Profitability U-TurnPayPal’s Strong Earnings Growth and Strategic Evolution This page (NYSE:PLX) was last updated on 5/20/2024 by MarketBeat.com Staff From Our PartnersThe Overlooked Retirement Asset You Probably Don’t OwnCrypto 101 MediaElon’s New Device is About to Shock the WorldInvestorPlaceBiden Nomination CANCELED?The Freeport SocietyUrgent Nvidia WarningAltimetryShocking: One AI startup's revenue could surge 4,735%Manward Press"The Biggest Drug Ever" Is ComingBehind the MarketsExposed: 10 CENT Crypto to Explode May 20th?True Market InsidersMost important medical advance in 100 yearsThe Oxford Club Adding Choose a watchlist: Watchlist My Default Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Please log in to your account or sign up in order to add this asset to your watchlist. Get 30 Days of MarketBeat All Access Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools: Best-in-Class Portfolio Monitoring View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio. Stock Ideas and Recommendations Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report. Advanced Stock Screeners and Research Tools Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis. Start Your 30-Day Free Trial Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
